重新审视类固醇类药物和阿司匹林在急性川崎病治疗中的作用  

Review the Role of Corticosteroids and Aspirin in the Treatment of Acute Kawasaki Disease

作　　者：冯建英 焦富勇[1] 杨勇 王繁 

机构地区：[1]陕西省人民医院儿童病院,陕西 西安

出　　处：《临床医学进展》2020年第7期1391-1396,共6页Advances in Clinical Medicine

摘　　要：目前认为,口服大剂量阿司匹林(ASP) (80~100 mg/kg∙d)与小剂量ASP (3~5 mg/kg∙d)在改善川崎病(Kawasaki disease, KD)急性期冠状动脉预后方面,并没有明显的差异。类固醇类药物适用于冠状动脉损伤预后不良和使用静脉丙种球蛋白(IVIG)治疗的耐药KD患儿,无论是在高危患儿的早期治疗,还是静脉注射IVIG失败后的抢救治疗,类固醇类药物均是有效的,并且耐受性良好。There is no significant difference between oral high-dose aspirin (ASP) (80 - 100 mg/kg∙d) and low-dose ASP (3 - 5 mg/kg∙d) in improving coronary prognosis in the acute phase of Kawasaki disease (KD). Corticosteroids are suitable for KD children with poor prognosis of coronary artery injury and intravenous gamma globulin (IVIG) resistance. Corticosteroids are effective and well tolerated in both early treatment of high-risk children and salvage treatment after failure of intravenous IVIG.

关 键 词：川崎病 类固醇类药物 阿司匹林 

分 类 号：R72[医药卫生—儿科]